These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23129326)

  • 1. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
    Kuepper R; Skinbjerg M; Abi-Dargham A
    Handb Exp Pharmacol; 2012; (212):1-26. PubMed ID: 23129326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.
    Winterer G
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S68-71. PubMed ID: 16508900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of extrastriatal dopamine D2 receptors in schizophrenia.
    Takahashi H; Higuchi M; Suhara T
    Biol Psychiatry; 2006 May; 59(10):919-28. PubMed ID: 16682269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurobiology of dopamine in schizophrenia.
    Guillin O; Abi-Dargham A; Laruelle M
    Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiologically based treatment interventions in schizophrenia.
    Lewis DA; Gonzalez-Burgos G
    Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor.
    Leriche L; Diaz J; Sokoloff P
    Neurotox Res; 2004; 6(1):63-71. PubMed ID: 15184107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?
    Benes FM
    Biol Psychiatry; 2009 Jun; 65(12):1003-5. PubMed ID: 19481640
    [No Abstract]   [Full Text] [Related]  

  • 11. Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia.
    Joyce JN; Meador-Woodruff JH
    Neuropsychopharmacology; 1997 Jun; 16(6):375-84. PubMed ID: 9165493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Involvement of central neurotransmission systems in schizophrenia].
    Martres MP
    Therapie; 2008; 63(3):177-85. PubMed ID: 18718209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complexity of the dopaminergic synapses and their modulation by antipsychotics.
    Leuner K; Müller WE
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the glutamate, GABA, and dopamine systems in relation to NRH-induced neurotoxicity.
    Benes FM
    Biol Psychiatry; 1995 Dec; 38(12):783-7. PubMed ID: 8750035
    [No Abstract]   [Full Text] [Related]  

  • 16. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
    Laruelle M; Kegeles LS; Abi-Dargham A
    Ann N Y Acad Sci; 2003 Nov; 1003():138-58. PubMed ID: 14684442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC; Seamans JK
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathway-Specific Dopamine Abnormalities in Schizophrenia.
    Weinstein JJ; Chohan MO; Slifstein M; Kegeles LS; Moore H; Abi-Dargham A
    Biol Psychiatry; 2017 Jan; 81(1):31-42. PubMed ID: 27206569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dopamine D(2) receptors for antipsychotic activity.
    Ginovart N; Kapur S
    Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.